Reviewer's report

Title: Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation

Version: 2 Date: 26 June 2009

Reviewer: Shlomo Melmed

Reviewer's report:

1. I am still concerned that Fig 4 is misleading as it does not compare other effective treatments. The absolute number of patients who have failed surgery and are non-responsive to somatostatin analogs is miniscule--far too small to garner such elegant curves!

2. I could not find ref 64 enumerating side effects in the ms. These must be cited.